An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Stopped early · Phase 2

Conditions studied: Endometrial Cancer

In brief

This is an open-label, multi-center, single-arm, two-period Phase 2 study. The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or persistent endometrial cancer, who have failed progestin monotherapy or who have been identified as Progesterone Receptor (PrR) negative. All patients must have endometrial cancer PrR status determined from an archival sample at Screening. The PrR status (positive or negative) will be determined by central laboratory by ImmunoHistoChemistry (IHC) testing. There are two treatment periods and a follow-up period within the study.

Key facts

Study ID

NCT03077698

Run by

Xenetic Biosciences, Inc.

People needed

25

Starts

2017-06-14

Expected to finish

2020-07-17

Last updated by the study team

2022-06-07

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female patients 18 years of age or older;
• Histologically confirmed serous carcinoma or endometrioid type of endometrial carcinoma (histological documentation of recurrence is not required);
• Recurrent or persistent progressive disease which is refractory to curative therapy or established treatments and cannot be treated with surgery or radiotherapy;
• Measurable disease, as defined by RECIST 1.1 criteria;
• At least one "target lesion" to be used to assess response, as defined by RECIST 1.1 criteria. Tumors within a previously irradiated field will be designated as "non-target" lesions unless previous progression is documented;
• Availability of archived tumor tissue sample that can be used for assessment of PrR status by the central laboratory;
• GOG (Gynecologic Oncology Group) performance status 0-2 (refer to Appendix A);
• Calculated Glomerular filtration rate ≥ 50 mL/min;
• Total bilirubin ≤ 2.5 times upper limit of normal (ULN);
• AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases);
• Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases);
• Albumin ≥ 3.0 mg/dL;
• Ability to take oral medication;
• Patients able to understand the nature of the study and who are willing to give written informed consent;
• And for Treatment Period 2 only: 1) Patients participating in Treatment Period 1 must have had disease progression after receiving at least 4 weeks of progestin therapy or 2) Patients must be determined as PrR negative status at Screening.

You may not qualify if…

• Mixed histology of the tumor or evidence of tumor histology other than serous carcinoma or endometrioid type of endometrial carcinoma;
• Concurrent systemic corticosteroid therapy;
• Concurrent oral contraceptive use / Women of childbearing potential not using highly effective means of contraception;
• Pregnancy confirmed by pregnancy test / Lactating women;
• Prior therapy with hormonal progestin agents;
• Patients who are candidates for treatment with standard chemotherapy agents (there is no limit to the number of lines of chemotherapy);
• History of blood clot;
• History of known bleeding disorder (i.e. disseminated intravascular coagulation or clotting factor deficiency);
• Major surgery within 4 weeks prior to the start of the study;
• Patients with clinically significant illnesses which, according to the Investigator, could compromise participation in the study;
• History of other clinically active malignancies within 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma, or squamous carcinoma of the skin.
• Known hypersensitivity or idiosyncratic reaction to any of the study drugs (Sodium Cridanimod, megestrol acetate, lidocaine) and excipients;
• Patients with known brain metastases;
• Patients currently receiving any other investigational agents;
• Patients currently receiving any other anticancer therapies;
• Participation in any other clinical study within the last 4 weeks prior to the start of the study

Where it is running

• Providence St. Joseph Medical Center - Gynecology — Burbank, California, United States
• University of California - Irvine Healthcare — Irvine, California, United States
• UCLA — Los Angeles, California, United States
• St. Josephs Heritage Healthcare — Santa Rosa, California, United States
• University of Colorado School of Medicine, Division of Gynecologic Oncology — Aurora, Colorado, United States
• Baptist MD Anderson Cancer Center — Jacksonville, Florida, United States
• Florida Hospital Cancer Institute — Orlando, Florida, United States
• Sarasota Memorial Health Care System — Sarasota, Florida, United States
• Northside Hospital [University Gynecologic Oncology] — Atlanta, Georgia, United States
• MUMC - Curtis and Elizabeth Anderson Cancer Institute — Savannah, Georgia, United States
• Saint Alphonsus Regional Medical Center — Boise, Idaho, United States
• RUSH University Medical Center — Chicago, Illinois, United States
• University of Kentucky, Markey Cancer Center — Lexington, Kentucky, United States
• Women's Cancer Care [Mary Bird Cancer Center at Tammany Parish Hospital] — Covington, Louisiana, United States
• St. Dominic-Jackson Memorial Hospital — Jackson, Mississippi, United States
• SUNY Downstate Medical Center — Brooklyn, New York, United States
• Columbia University Medical Center — New York, New York, United States
• Wake Forest Baptist Health — Winston-Salem, North Carolina, United States
• University of Cincinnati Cancer Institute-UC Health Barrett Center — Cincinnati, Ohio, United States
• Oklahoma Cancer Specialists and Research Institute, LLC — Tulsa, Oklahoma, United States
• Magee Women's Hospital (UPMC) — Pittsburgh, Pennsylvania, United States
• Rapid City Regional Cancer Care — Rapid City, South Dakota, United States
• UT Southwestern — Dallas, Texas, United States
• UT Galveston; University of Texas Medical Branch (UTMB) — Galveston, Texas, United States
• Seattle Cancer Care Alliance / University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.